Moonlight begins SURVEYOR Phase I trial for peanut allergy

Moonlight Therapeutics has begun the SURVEYOR Phase I clinical trial to assess MOON101, an investigational immunotherapy for peanut allergy. The study marks the first-in-human trial of MOON101 and plans to enrol up to 40 participants at various clinical sites across the US. The trial targets those with physician-confirmed peanut allergy, covering an age range from four to 55 years. Credit: luchschenF / Shutterstock.com. Moonlight Therapeutics has begun the SURVEYOR Phase I clinical trial to assess MOON101, an investigational immunotherapy for peanut allergy. The ascending-dose, open-label trial represents the transition of MOON101 into clinical-stage development and will evaluate its tolerability and…

Source: Clinical Trials Arena